Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genetic variation in IL28B and treatment outcome in HBeAg-positive and -negative chronic hepatitis B patients treated with Peg interferon alfa-2a and adefovir.
de Niet A, Takkenberg RB, Benayed R, Riley-Gillis B, Weegink CJ, Zaaijer HL, Koot M, Jansen PL, Beld MG, Lopatin U, Reesink HW. de Niet A, et al. Among authors: weegink cj. Scand J Gastroenterol. 2012 Apr;47(4):475-81. doi: 10.3109/00365521.2011.648952. Epub 2012 Jan 23. Scand J Gastroenterol. 2012. PMID: 22263608 Clinical Trial.
Inflammatory markers neopterin and alanine aminotransferase in HCV patients treated with HCV NS3.4A protease inhibitor telaprevir (VX-950) and/or peginterferon alfa-2a.
Gelderblom HC, Zeuzem S, Weegink CJ, Forestier N, Mcnair L, Purdy S, Dijkgraaf MG, Jansen PL, Reesink HW. Gelderblom HC, et al. Among authors: weegink cj. Scand J Gastroenterol. 2008;43(9):1122-7. doi: 10.1080/00365520802044210. Scand J Gastroenterol. 2008. PMID: 18609142 Clinical Trial.
Detection of hepatitis B virus covalently closed circular DNA in paraffin-embedded and cryo-preserved liver biopsies of chronic hepatitis B patients.
Takkenberg RB, Zaaijer HL, Menting S, Weegink CJ, Terpstra V, Cornelissen M, Dijkgraaf MG, Jansen PL, Reesink HW, Beld MG. Takkenberg RB, et al. Among authors: weegink cj. Eur J Gastroenterol Hepatol. 2010 Aug;22(8):952-60. doi: 10.1097/MEG.0b013e3283376a63. Eur J Gastroenterol Hepatol. 2010. PMID: 20150816
Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir.
Takkenberg RB, Jansen L, de Niet A, Zaaijer HL, Weegink CJ, Terpstra V, Dijkgraaf MG, Molenkamp R, Jansen PL, Koot M, Rijckborst V, Janssen HL, Beld MG, Reesink HW. Takkenberg RB, et al. Among authors: weegink cj. Antivir Ther. 2013;18(7):895-904. doi: 10.3851/IMP2580. Antivir Ther. 2013. PMID: 23639931 Clinical Trial.
Novel therapies in hepatitis B and C.
Takkenberg B, de Bruijne J, Weegink C, Jansen P, Reesink H. Takkenberg B, et al. Curr Gastroenterol Rep. 2008 Feb;10(1):81-90. doi: 10.1007/s11894-008-0013-z. Curr Gastroenterol Rep. 2008. PMID: 18417047 Review.
Sustained virological response in chronic hepatitis C patients after a 6- and a 36-month interferon-alpha2b treatment schedule: a multicenter, randomized, controlled study.
Damen M, Weegink CJ, Mauser-Bunschoten EP, Cuypers HT, Hermus MC, Sillekens P, Haan E, van den Berg HM, Bresters D, Lelie PN, Chamuleau RA, Reesink HW. Damen M, et al. Among authors: weegink cj. Scand J Gastroenterol. 2001 Jan;36(1):97-104. doi: 10.1080/00365520150218129. Scand J Gastroenterol. 2001. PMID: 11218246 Clinical Trial.
50 results